The systemic immune-inflammation index (SII) is an integrated biomarker which may indicate systemic inflammation and local immune responses in the whole human body. Inflammation plays a central role in the progression of nonalcoholic fatty liver disease (NAFLD), and the upregulation of inflammatory mediators is strongly associated with hepatic steatosis and fibrosis.
This cross-sectional study by Xie R, Xiao M, Li L, et al. aimed to examine the possible association between SII and hepatic steatosis and fibrosis. It used controlled attenuation parameter (CAP) as well as liver stiffness measurement (LSM) to assess hepatic steatosis and fibrosis, respectively.
Increased SII levels are significantly associated with hepatic steatosis, but not with liver fibrosis. An inverted U-shaped association between SII and CAP with an inflection point of 687.059 further indicates that SII is an independent crisis factor for hepatic steatosis when the SII is inferior to 687.059.